DROXIDOPA
- CAS No.
- 23651-95-8
- Chemical Name:
- DROXIDOPA
- Synonyms
- L-threo-3,4-Dihydroxyphenylserine;Droxidopa (JAN);l-dops;SM 5688;roxidopa;DROXIDOPA;Droxydopa;l-threodops;Droxidopa>Droxidopa-13C6
- CBNumber:
- CB1699324
- Molecular Formula:
- C9H11NO5
- Molecular Weight:
- 213.19
- MDL Number:
- MFCD00799030
- MOL File:
- 23651-95-8.mol
- MSDS File:
- SDS
Melting point | 232-235° (dec); mp 229-232° (dec) (Ohashi) |
---|---|
alpha | D20 -39° (c = 1 in 1N aq HCl); D20 -42.0° (c = 1 in 1N aq HCl) |
Boiling point | 549.8±50.0 °C(Predicted) |
Density | 1.608±0.06 g/cm3(Predicted) |
storage temp. | -20°C |
solubility | DMSO: ≥3mg/mL |
pka | 2.09±0.24(Predicted) |
form | powder |
color | white to tan |
Merck | 14,3457 |
Stability | Hygroscopic |
CAS DataBase Reference | 23651-95-8 |
FDA UNII | J7A92W69L7 |
ATC code | C01CA27 |
SAFETY
Risk and Safety Statements
Symbol(GHS) | GHS07 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Signal word | Warning | |||||||||
Hazard statements | H315-H319-H335 | |||||||||
Precautionary statements | P261-P264-P271-P280-P302+P352-P305+P351+P338 | |||||||||
Hazard Codes | Xi | |||||||||
Risk Statements | 36/37/38 | |||||||||
Safety Statements | 26 | |||||||||
WGK Germany | 3 | |||||||||
RTECS | VT9626010 | |||||||||
HS Code | 29225090 | |||||||||
NFPA 704 |
|
DROXIDOPA price More Price(22)
Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|---|
Sigma-Aldrich | D9446 | L-DOPS ≥98% (HPLC) | 23651-95-8 | 5mg | $147 | 2024-03-01 | Buy |
Sigma-Aldrich | D9446 | L-DOPS ≥98% (HPLC) | 23651-95-8 | 25mg | $583 | 2024-03-01 | Buy |
TCI Chemical | D4235 | Droxidopa >98.0%(HPLC)(T) | 23651-95-8 | 50mg | $168 | 2024-03-01 | Buy |
TCI Chemical | D4235 | Droxidopa >98.0%(HPLC)(T) | 23651-95-8 | 200mg | $480 | 2024-03-01 | Buy |
Cayman Chemical | 23779 | Droxidopa ≥95% | 23651-95-8 | 1mg | $32 | 2024-03-01 | Buy |
DROXIDOPA Chemical Properties,Uses,Production
Description
Droxidopa is a synthetic amino acid precursor of (-)-norepinephrine which is absorbed from the gut and metabolized to norepinephrine. In Parkinsonian patients, droxidopa added to existing levodopa/decarboxylase inhibitor therapy produces significant improvements in retropulsion, dysarthria and muscular rigidity refractory to other treatments; however, tremor was unaffected.
Description
Droxidopa (L-DOPS) is a synthetic precursor and prodrug of the neurotransmitter norepinephrine. It is transformed into norepinephrine through the action of DOPA decarboxylase. L-DOPS increases norepinephrine levels in the rat heart following intraperitoneal administration and in the brain following intracerebroventricular administration at doses of 125 and 100 μg/animal, respectively. It increases arterial pressure and mesenteric arterial resistance in rats with ligated portal vein or biliary ducts when used at doses of 25-50 mg/kg. L-DOPS crosses the blood brain barrier, however, its effects can be blocked by the peripherally-restricted DOPA decarboxylase inhibitor carbidopa , indicating that the mechanism is peripheral. Formulations containing droxidopa are used in the treatment of neurogenic orthostatic hypotension.
Chemical Properties
Off-White Solid
Originator
Sumitomo (Japan)
Uses
Droxidopa is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline).
Uses
The L-threo-form Droxidopa. A synthetic amino acid precursor of Norepinephrine (N674500). Antiparkinsonian.
Uses
L-DOPS has been administered for clinical trial studies in mice with amyloid pathology.
Definition
ChEBI: A serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension
brand name
DOPS
General Description
L-DOPS, also called L-threo 3,4-Dihydroxyphenylserine or droxidopa is a catecholamine. L-DOPS has many clinical advantages and may be useful for treating norepinephrine deficiency. It is used for treating neurogenic orthostatic hypotension and improves norepinephrine levels. L-DOPS mediates reduction of amyloid plaques and could have a therapeutic potential for treating amyloid pathology.
Biochem/physiol Actions
L-DOPS is a norepinephrine precursor in vivo.
DROXIDOPA Preparation Products And Raw materials
Raw materials
Preparation Products
Supplier | Tel | Country | ProdList | Advantage | |
---|---|---|---|---|---|
Hebei Chuanghai Biotechnology Co,.LTD | +86-13131129325 | sales1@chuanghaibio.com | China | 5892 | 58 |
Henan Fengda Chemical Co., Ltd | +86-371-86557731 +86-13613820652 | info@fdachem.com | China | 20287 | 58 |
Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | info@tianfuchem.com | China | 21634 | 55 |
BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19553 | 58 |
Alchem Pharmtech,Inc. | 8485655694 | sales@alchempharmtech.com | United States | 63687 | 58 |
CONIER CHEM AND PHARMA LIMITED | +8618523575427 | sales@conier.com | China | 49374 | 58 |
Hebei Mojin Biotechnology Co., Ltd | +86 13288715578 +8613288715578 | sales@hbmojin.com | China | 12839 | 58 |
TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | marketing@targetmol.com | United States | 32165 | 58 |
Hefei TNJ Chemical Industry Co.,Ltd. | +86-0551-65418671 +8618949823763 | sales@tnjchem.com | China | 34553 | 58 |
Xi'an MC Biotech, Co., Ltd. | 029-89275612 +8618991951683 | mcbio_sales@163.com | China | 2251 | 58 |
View Lastest Price from DROXIDOPA manufacturers
Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
---|---|---|---|---|---|---|---|---|
2024-11-19 | Droxidopa
23651-95-8
|
US $32.00-98.00 / mg | 98.12% | 10g | TargetMol Chemicals Inc. | |||
2024-10-11 | DROXIDOPA
23651-95-8
|
US $19.00 / KG | 1KG | 99.% | 50 ton | Hebei Chuanghai Biotechnology Co,.LTD | ||
2024-04-23 | DROXIDOPA
23651-95-8
|
US $8.00-6.00 / kg | 1kg | 99% | g-kg-tons, free sample is available | Henan Fengda Chemical Co., Ltd |